查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
qPCR 试剂市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)
市场调查报告书
商品编码
1273447

qPCR 试剂市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

qPCR Reagents Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，qPCR 试剂市场预计将以 7.9% 的复合年增长率增长。

由于对聚合□链反应测试的需求增加以及 COVID-19 导致目标患者人数显着增加，qPCR 试剂产品市场正在增长。 对于 COVID-19 的诊断，鼻咽拭子等上呼吸道样本和最近使用唾液的免疫学检测 qPCR 已成为最常见和最可靠的检测方法。 因此，使用 qPCR 试剂进行疾病诊断已成为大流行管理的主要焦点。 根据 2021 年 5 月的 Cytiva 新闻稿，一家 qPCR 试剂製造商必须立即将产量提高 50 倍，以满足对 COVID-19 测试的需求。 因此，在大流行期间对 qPCR 试剂的需求大幅增加，对市场增长产生了积极影响。 现在，随着 COVID-19 数量的减少，市场需求正在放缓。 此外，由于慢性病患病率上升和 qPCR 检测技术进步，预计该市场在预测期内将会增长。

传染病和遗传病患病率的上升增加了对有助于采取预防措施的诊断测试的需求。 人口老龄化也增加了对基因检测的需求。 例如，根据“Breast Cancer Factsheet Now 2021”，英国每年约有 55,000 名女性和 370 名男性被诊断出患有乳腺癌。 乳腺癌在英国夺去了大约 600,000 人的生命。 到 2030 年，这一数字预计将上升到 120 万。 此外，澳大利亚艾滋病组织联合会2022年11月发布的报告估计，2021年澳大利亚将有29460名艾滋病病毒感染者。 在这 29,460 人中，估计到 2021 年底将有 91% 得到诊断。 因此，随着传染病的流行，诊断测试的需求预计会增加，从而推动预测期内市场的增长。

此外，由于老年人口更容易感染传染病和慢性病，因此预计不断增长的老年人口将推动市场扩张。 预计老年人口的增加将在预测期内推动市场增长。 例如，根据联合国人口基金会公布的2022年统计数据，美国大部分的生活人口年龄在15至64岁之间，到2022年将占到65%。 此外，根据同一数据，到 2022 年，17% 的人口将超过 65 岁。 因此，传染病在老龄化人口中普遍存在，推动了对 qPCR 试剂的需求。

因此，传染病负担的增加和人口老龄化将支持预测期内的市场扩张。 然而，qPCR 设备的高成本和缺乏操作 qPCR 设备的高技术专长限制了市场增长。

qPCR试剂市场趋势

染料基qPCR试剂有望主导市场

荧光 DNA 结合染料的使用是科学家使用的最简单和最常用的 qPCR 方法之一。 将染料添加到反应中，并在每个 PCR 循环后测量荧光。 在双链 DNA 存在的情况下，这些染料的荧光会急剧增加，从而可以通过荧光信号的增加来监测 DNA 合成。

基于染料的定性诊断 PCR 用于快速检测诊断传染病、癌症和遗传异常等的核酸。 例如，根据“Breast Cancer Factsheet Now 2021”，英国每年约有 55,000 名女性和 370 名男性被诊断出患有乳腺癌。 乳腺癌在英国夺去了大约 600,000 人的生命。 到 2030 年，这一数字预计将上升到 120 万。 因此，癌症疾病负担的增加有望推动这一领域的增长。

此外，预计市场进入者推出的产品将在预测期内支持市场扩张。 例如，2021 年 12 月，Biotium 宣布了用于 qPCR 和 HRM 的“EvaRuby”染料。 这种光谱学上独特的红色荧光嵌入染料可以併入基于探针的 qPCR 测定中，扩展基于探针的 qPCR 的多重选择。 EvaRuby 染料兼容~470nm 激发和~610nm 发射滤光片。

因此，上述所有因素和产品发布预计将在预测期内推动该细分市场的增长。

qPCR试剂市场-IMG1

预计在预测期内北美将占据很大的市场份额

北美占据了 PCR 试剂市场的主要市场份额。 疾病发病率上升、老年人口增加（老龄化）和技术进步是推动市场增长的因素。 尤其是近期，疫情也提振了qPCR试剂市场。 例如，根据美国癌症协会2022年1月发布的《Cancer Facts and Figures 2022》，估计2022年将诊断出190万新癌症患者，其中180,000为前列腺癌，6,670，其次是肺癌和169,870，女性乳腺癌有 144,490。 癌症患病率的增加和其他慢性病的高负担增加了对准确诊断和治疗的需求。 这可能会增加 qPCR 试剂并最终促进市场增长。

此外，根据加拿大政府于2021年11月发布的统计数据，2021年约有229,200名加拿大人被诊断出患有癌症，其中前列腺癌是2021年最常见的癌症，预计将继续成为最常见的癌症确诊为癌症，占确诊总数的46%。 根据相同的数据，每 8 名女性中就有 1 名会在一生中的某个时刻被诊断出患有乳腺癌。 因此，随着癌症患者数量的增加，对早期诊断的需求也将增加，从而推动预测期内对 qPCR 试剂的需求。

此外，市场进入者推出的产品有望支持市场增长。 例如，2022 年 2 月，New England Biolabs (NEB) 推出了 Fluorogenics 的第一个冻干产品，即 LyoPrime Luna Probe One-Step RT-qPCR Mix with UDG。 这种冻干主混合物具有与我们发布的液体 4X 混合物相似的适应性和稳健性能，能够以室温稳定形式对目标 RNA 序列进行灵敏和线性实时检测。

因此，所有上述因素，例如日益增加的传染病负担，预计将推动该地区市场的增长。

qPCR试剂市场-IMG2

qPCR试剂行业概况

qPCR 试剂市场竞争激烈，由几家主要参与者组成。 拥有更多研究资金和更好分销系统的市场领导者正在确立其在市场中的地位。 该市场的主要参与者包括 F. Hoffman-La Roche Ltd、Agilent Technologies、Bio-Rad Laboratories Inc、Merck KGaA（Sigma Aldrich Corporation）和 Thermo Fisher Scientific Inc。

其他福利：

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 调查假设和市场定义
  • 本次调查的范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 传染病和遗传病的发病率增加
    • 老年人口增加
    • 越来越关注人类基因组计划
  • 市场製约因素
    • 试剂和 qPCR 设备成本高
    • 缺乏操作 qPCR 设备的技术专长
  • 波特五力
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（市场规模：金额）

  • 通过检测方法
    • 染料基 qPCR 试剂
    • 基于探针和引物的 qPCR 试剂
  • 按包装类型
    • qPCR 核心试剂盒
    • qPCR 预混液
  • 最终用户
    • 医院和诊断中心
    • 研究机构和学术机构
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Kaneka Eurogentec S.A.
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • F. Hoffman-La Roche Ltd.
    • Promega Corporation
    • Quanta Biosciences, Inc.
    • Sigma-Aldrich Corporation（Merck KGaA）
    • Takara Bio Inc.
    • Thermo Fisher Scientific

第7章 市场机会与将来动向

简介目录
Product Code: 67598

The qPCR reagents market is expected to register a CAGR of 7.9% over the forecast period.

The market for qPCR reagent products has increased as a result of COVID-19, owing mostly to rising demand for polymerase chain reaction tests and a significant increase in the target patient group. The qPCR test, which uses nasopharyngeal swabs or other upper respiratory tract specimens, such as throat swabs or, more recently, saliva for immunology assays, has been the most commonly used and reliable test for COVID-19 diagnosis. As a result, disease diagnosis utilizing qPCR reagents emerged as a primary emphasis for pandemic management. The press release by Cytiva in May 2021 revealed that a qPCR reagent manufacturing company had to immediately raise output 50-fold to satisfy the demand for COVID-19 tests. Thus, during the pandemic, the demand for qPCR reagents tremendously increased, which positively influenced the market's growth. Currently, the market demand has slowed down as the number of COVID-19 has declined. Moreover, it is expected that the market will grow over the forecast period due to the rise in the prevalence of chronic diseases and technological advances in the qPCR test.

The rising incidence of infectious and genetic diseases has increased the demand for diagnostic tests that may help people take precautionary measures. The growing geriatric population has also increased the demand for genetic tests. For instance, according to the Breast Cancer Factsheet Now 2021, around 55,000 women and 370 men in the United Kingdom are diagnosed with breast cancer yearly. Breast cancer has claimed the lives of an estimated 600,000 people in the United Kingdom. This figure is expected to climb to 1.2 million by 2030. Additionally, according to the Australian Federation of AIDS Organizations Report published in November 2022, in 2021, it was estimated that there were 29,460 people with HIV in Australia. Of these 29,460 people, an estimated 91% will have been diagnosed by the end of 2021. Thus, with the growing prevalence of infectious diseases, the demand for diagnostic tests is expected to increase, which propels the growth of the market over the forecast period.

Moreover, the growing geriatric population is expected to support market expansion as this population is more susceptible to infectious and chronic diseases. The increasing geriatric population is likely to increase market growth over the forecast period. For instance, according to the 2022 statistics published by the United Nations Population Fund, in the United States, a large proportion of the living population is aged 15-64 and accounts for 65% in 2022. Furthermore, according to the same source, 17% of the population will be 65 or older in 2022. Thus, infectious diseases are more prevalent in the geriatric population, boosting the demand for qPCR reagents.

Thus, the growing burden of infectious diseases and the ageing population support market expansion over the forecast period. However, the high cost of qPCR equipment and the lack of high technical expertise to operate qPCR equipment have been restraining market growth.

qPCR Reagents Market Trends

Dye-Based qPCR Reagents are Expected to Dominate the Market

The use of fluorescent DNA-binding dyes is one of the most straightforward and common qPCR approaches used by scientists. A dye is added to the reaction, and fluorescence is measured at each PCR cycle. Because the fluorescence of these dyes increases dramatically in the presence of double-stranded DNA, DNA synthesis can be monitored as an increase in fluorescent signal.

Dye-based diagnostic qualitative PCR is applied to rapidly detect nucleic acids that are diagnostic of, for example, infectious diseases, cancer, and genetic abnormalities. For instance, according to the Breast Cancer Factsheet Now 2021, around 55,000 women and 370 men in the United Kingdom are diagnosed with breast cancer yearly. Breast cancer has claimed the lives of an estimated 600,000 people in the United Kingdom. This figure is expected to climb to 1.2 million by 2030. Thus, the growing burden of cancer diseases is expected to propel the segment's growth.

Additionally, product launches by the market players are expected to support the market expansion over the forecast period. For instance, in December 2021, Biotium released 'EvaRuby' Dye for qPCR and HRM. This spectrally unique red fluorescent intercalating dye can be incorporated into probe-based qPCR assays, expanding multiplexing options for probe-based qPCR. EvaRuby Dye is compatible with ~470 nm excitation and ~610 nm emission filters.

Thus, all aforementioned factors with product launches are expected to boost segment growth over the forecast period.

qPCR Reagents Market - IMG1

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America holds the major market share in the PCR reagent market. The rising incidence of diseases, the elderly population (aging), and technological advancements are attributed to market growth. Especially in recent times, pandemics have also boosted the qPCR reagent market. For instance, according to Cancer Facts and Figures 2022, published in January 2022 by the American Cancer Society, an estimated 1.9 million new cancer cases will be diagnosed in 2022, among which prostate cancer is estimated to be 186,670, followed by 169,870 cases of lung cancer, and 144,490 cases of female breast cancer. The increased prevalence of cancer and the high burden of other chronic diseases increase the demand for accurate diagnosis and treatment. This is likely to increase the qPCR reagent, ultimately boosting the market growth.

Furthermore, according to statistics published by the Government of Canada and released in November 2021, about 229,200 Canadians were diagnosed with cancer in 2021, and prostate cancer is expected to remain the most diagnosed cancer, accounting for 46% of all cancer diagnoses in 2021. According to the same source, breast cancer affects one out of every eight women at some point in their lives. Thus, as the number of cancer cases rises, so does the demand for early diagnosis, driving demand for qPCR reagents over the projection period.

Additionally, product launches by the market players are expected to support market growth. For instance, in February 2022, New England Biolabs (NEB) released the LyoPrime Luna Probe One-Step RT-qPCR Mix with UDG, its first lyophilized product manufactured by Fluorogenics. This lyophilized master mix has the same adaptable characteristics and strong performance as the previously published liquid 4X mix, allowing for sensitive, linear real-time detection of target RNA sequences in a room temperature-stable format.

Thus, all aforementioned factors, such as the growing burden of infectious diseases, are expected to boost the growth of the market in the region.

qPCR Reagents Market - IMG2

qPCR Reagents Industry Overview

The qPCR reagents market is highly competitive and consists of a few major players. Market leaders with more funds for research and better distribution system have established their position in the market. The key Companies in this market are F. Hoffman-La Roche Ltd, Agilent Technologies, Bio-Rad Laboratories Inc, Merck KGaA (Sigma Aldrich Corporation), and Thermo Fisher Scientific Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence of Infectious Diseases and Genetic Disorders
    • 4.2.2 Growing Geriatric Population
    • 4.2.3 Increasing Focus on Human Genome Projects
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Reagents and qPCR Equipment
    • 4.3.2 Lack of Technical Expertise to Operate the qPCR instrument
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Millions)

  • 5.1 By Detection Method
    • 5.1.1 Dye-Based qPCR Reagents
    • 5.1.2 Probes and Primer-Based qPCR Reagents
  • 5.2 By Packaging Type
    • 5.2.1 qPCR Core Kits
    • 5.2.2 qPCR Mastermixes
  • 5.3 By End-User
    • 5.3.1 Hospitals & Diagnostic Centers
    • 5.3.2 Research Laboratories & Academic Institutes
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Kaneka Eurogentec S.A.
    • 6.1.2 Agilent Technologies, Inc.
    • 6.1.3 Bio-Rad Laboratories, Inc.
    • 6.1.4 F. Hoffman-La Roche Ltd.
    • 6.1.5 Promega Corporation
    • 6.1.6 Quanta Biosciences, Inc.
    • 6.1.7 Sigma-Aldrich Corporation (Merck KGaA)
    • 6.1.8 Takara Bio Inc.
    • 6.1.9 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS